Celltrion’s Eydenzelt Shows Long-Term Efficacy, Accelerates $13B Market Entry
[Song Young Doo, Edaily Repoeter] Celltrion announced on Sept.
3 that results from the 52-week global Phase 3 trial of Eydenzelt, its biosimilar to Eylea(aflibercept), have been published in the international ophthalmology journal Ophthalmology and Therapy.
The study evaluated 348 patients with diabetic macular edema(DME), comparing Eydenzelt with the reference drug in terms of efficacy, long-term outcomes, and safety.
뉴스픽의 주요 문장 추출 기술을 사용하여 “이데일리” 기사 내용을 3줄로 요약한 결과입니다. 일부 누락된 내용이 있어 전반적인 이해를 위해서는 본문 전체 읽기를 권장합니다.
